World-first MND drug trial offers hope to those living with the disorder

A world-first trial for a drug that researchers hope could not only slow down the progression but actually reverse the condition of motor neurone disease is currently in phase two of clinical trials. If successful, American company Spinogenix drug SPG302 would be the first regenerative treatment for the devastating and rapid neurodegenerative disease. Spinogenix founder Dr Stella Sarraf joined Sky News Business Editor Ross Greenwood to discuss the ongoing groundbreaking trial. “SPG302 is developed as a pill and we aim to restore function by working and treating the synapses or connections in the brain that are fundamental and ground zero for many of these conditions,“ Ms Sarraf said. “It provides hope to restore function and also provides a means to give function back to the patients and so this is something that’s very unique and different than other approaches that just seem to just halt the disease and symptom management. “We’re very excited about where we’re headed and the possibilities are potentially endless.“